Gene Therapy For Lethal Glycogen Storage Disease Wins EMA PRIME Designation
Ten products have been granted PRIME designation so far this year
Investigational products from Ultragenyx and MinervaX secured a place on the European Medicines Agency’s priority medicines scheme this month.
You may also be interested in...
The Danish biotech has secured more funding for a late-stage program to advance its vaccine against Group B streptococcus, which is in a race for approval with Pfizer's product.
This year’s first designations under the European Medicines Agency’s priority medicines scheme have gone to a maternal vaccine for an infection in newborns and a treatment for an ultra-rare bone disorder.
Outlook Therapeutics is hoping to secure EU marketing approval for the first ophthalmic formulation of bevacizumab.